Slide 1: Corum transformation continues
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au Market Release 18 August 2021 Corum transformation continues Corum Group Limited (ASX: COO) (Corum) is pleased to announce its full year results for FY21. • Group revenue $13.4m UP 26% on pcp • U
Slide 2: About Corum Group
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au This announcement has been authorised for lodgment by Julian Sallabank, Managing Director For further information contact: Julian Sallabank, Managing Director Investor email: Investor.Relations@c
Slide 3: Corum Group Limited FY21 Results
Corum Group Limited FY21 Results 18 August 2021
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Corum Group Limited (COO or the assurance that the results, performance or achievements expressed or implied by Company or Corum). It should not be considered as an offer or invitation to the forward-looking statements contained in
Slide 5: FY21 Key Highlights
FY21 Key Highlights Financials • Revenue $13,382k, an increase of 26% on pcp • Heath Services $11,875k, up 35% on pcp • eCommerce $1,507k, down 17% on pcp • Underlying EBITDA $4.4m(1) compared to $1.3m(2) in pcp, up 237% • Underlying NPAT of $2.2m(3) compared to $0.2m(4) in pcp, up 1,105% • Underlyi
Slide 6: FY21 Key Highlights
FY21 Key Highlights PharmX Acquisition • Acquisition of the 57% equity in PharmX that Corum did not already own • This acquisition was earnings per share accretive in the first year, as forecast Capital Raising • Corum undertook a 1 for 3 Non-Renounceable Rights issue (“Offer”) to raise $5.6 million
Slide 7: Our Pharmacy Software Solutions
Our Pharmacy Software Solutions Corum Health is a key enabler of Australian community pharmacy through it’s Dispense, Point of Sale and Head Office pharmacy digital infrastructure Solutions • Medication dispense systems are highly regulated • ePrescribing ready in a post COVID environment Dispense •
Slide 8: Pharmacy Software Opportunities
Pharmacy Software Opportunities Focus on regaining market share Entry through Head Office expertise • 90% of pharmacies are now affiliated with a group, banner, brand or buying group which supports this approach • Regaining market share by targeting these groups through our relationships and market
Slide 9: PharmX Overview
PharmX Overview PharmX is the pre-eminent electronic ordering gateway for Australian pharmacy with a long track record of delivering the stability and reliability required by the high order volumes of pharmacies Key Pharmacy Benefits Key Supplier Benefits • Access all wholesalers • Single access poi
Slide 10: PharmX Opportunities
PharmX Opportunities Renewed strategic focus has delivered enhanced growth opportunities –the past 3 years of equity holder litigation that was a significant distraction to the strategic focus of PharmX, has been resolved through the acquisition Capital Investment Additional Services Corum will cont
Slide 11: eCommerce
eCommerce Corum eCommerce provides its clients a simple and efficient outsourced payment processing platform Our eCommerce Solution • Secure PCI compliant payment ReConnect oneCard gateway Secure payment solution primarily used by Real Estate agents without the need to maintain their own secure paym
Slide 12: Financials
Financials
Slide 13: FY21 Financial Snapshot
FY21 Financial Snapshot Sales Revenue ($000’s) Results1 FY20 FY21 ∆ PCP Revenue $10,643 $13,382 26% H2 Health Services2 $8,819 $11,875 35% $7,352 H2 $6,473 H2 H2 $6,723 H2 eCommerce $1,824 $1,507 -17% $5,348 H2 $4,813 $4,605 H1 H1 H1 Expenses ($9,648) ($10,320) 7% $8,201 H1 H1 $7,034 H1 $5,828 $5,32
Slide 14: Underlying Result Reconciliation
Underlying Result Reconciliation NPAT FY21 EBITDA FY21 Underlying EBITDA $4,435 Revenue $13,382 Depreciation & Amortisation, interest and tax ($2,230) Expenses ($10,320) Underlying NPAT $2,205 PharmX + BAMM legal costs / restructuring / ($1,373) Reported EBITDA $3,062 redundancy PharmX + BAMM legal
Slide 15: Continued Positive Cashflow
Continued Positive Cashflow • Operating cashflow improvement has Net cash from / (Used in) Operating Activities (#039;000)1 been a key focus for new Board and has delivered positive results in FY21 $903 $559 • FY21 operating cashflow of $1.5m vs $191 prior year operating cashflow loss of $(1.1)m • Rece
Slide 16: FY21 Summary
FY21 Summary Refreshed Board & Profitability restored & Platform For Growth Healthtech Focus management with generating cash significant equity First revenue uplift since Over the past 12 months Provides investors exposure Corum has strengthened its FY16 and EBITDA Margin Corum has put in place to a
Slide 17: Questions
Questions
Slide 18: Appendix
Appendix
Slide 19: Corporate Overview
Corporate Overview Corum Group Limited (ASX:COO) Capital Structure Share Price 8.0cps Shares on Issue (m) 596.8 Market Capitalisation $47.74m Options / Perf Rights (m) 4.0 Enterprise Value (Cash 30/06/21) $41.26m Diluted Issued Capital (m) 600.8 Share Price Performance1 12c 8 Volume (m) 8c 4 4c 0c 0
Slide 20: Board & Management
Board & Management Nick England - Chairman Nick has over 35 years of consulting and senior executive experience in Australia, the UK and Europe. Nick held senior management roles with Alliance UniChem PLC (now AB Walgreens) which operates more than 18,000 pharmacies across multiple countries. As Gro
Slide 21: Board & Management
Board & Management Jayne Shaw - Non-Executive Director Ms Shaw has significant experience in healthcare management and an experienced clinical background in nursing. Ms Shaw has acted in senior management roles in two Australian private hospitals and established an Australian and international consu
Slide 22: Profit & Loss
Profit & Loss Profit & Loss (A$000's) H1'20 H2'20 FY'20 H1'21 H2'21 FY21 ∆ PCP Revenue $5,011 $5,632 $10,643 $6,642 $6,740 $13,382 26% Health $4,056 $4,763 $8,819 $5,862 $6,013 $11,875 34.7% eCommerce $955 $869 $1,824 $780 $727 $1,507 -17.4% Expenses Materials and consumables ($574) ($629) ($1,203)
Slide 23: Balance Sheet
Balance Sheet Balance Sheet (A$000's) FY'20 FY'21 Current assets Cash and cash equivalents $2,323 $6,478 Trade and other receivables $3,826 $864 Inventories $64 $34 Income tax receivable $1,700 $1,548 Other assets $1,928 $1,492 Total $9,841 $10,416 Non-current assets Investments $2,686 - Property, p
Slide 24: Cashflow
Cashflow Cash flow (A$000's) FY’20 FY’21 Cash flows from operating activities Receipts from customers $9,773 $13,887 Payments to suppliers and employees ($11,238) ($12,534) Interest and other revenue received $341 $108 Income tax paid ($281) ($272) Research and development incentive $1,774 $1,973 Ne
Slide 25: Share Registry
Share Registry Top holders as of 12 August 2021 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 95,746,043 16.04% 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.05% 3 NATIONAL NOMINEES LIMITED 38,033,657 6.37% 4 MERSAULT PTY LTD <THE ENGLAND FAMILY S/F A/C> 26,766,667 4.49% 5 BENKI PT
Slide 26: Corum Group Limited
Corum Group Limited Contact: Investor.Relations@corum.com.au